Reduced pathology following infection with transgenic Leishmania major expressing murine CD40 ligand

Infection and Immunity

Volumn 75, Issue 6, 2007, Pages 3140-3149

  Field, Ann E ^a   Wagage, Sagie ^a   Conrad, Sean M ^a   Mosser, David M ^a,b  

^a Bldg 142   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOGENICITY; INOCULATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE VIRULENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; WILD TYPE;

ANIMALS; ANTIGENS, CD40; CD40 LIGAND; LEISHMANIA MAJOR; MICE; MICE, INBRED BALB C; ORGANISMS, GENETICALLY MODIFIED; PROTOZOAN VACCINES; VACCINATION;

EID: 34249863582     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00160-07     Document Type: Article

References (43)

1. Afonso, L. C. C., and P. Scott. 1993. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61:2952-2959.
2. Anderson, C. F., A. E. Field, L. Gutirrez-Kobeh, D. M. Mosser, and M. Lucas. 2004. T cell biasing by activated dendritic cells. J. Immunol. 173:955-961.
3. Banchereau, J., F. Bazan, D. Blanchard, F. Briere, J. P. Galizzi, K. C. Van, Y. J. Liu, F. Rousset, and S. Saeland. 1994. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12:881-922.
4. Campbell, K. A., W. C. Fanslow, S. G. Reed, P. J. Ovendale, M. K. Kennedy, and C. R. Maliszewski. 1996. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 4:283-289.
5. Chamekh, M., V. Vercruysse, M. Habib, M. Lorent, M. Goldman, A. Allaoui, and B. Vray. 2005. Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection. Infect. Immun. 73:6552-6561.
6. Chatelain, R., K. Varkila, and R. L. Coffman. 1992. IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148:1182-1187.
7. Chen, G., P. A. Darrah, and D. M. Mosser. 2001. Vaccination against the intracellular pathogens Leishmania major and L. amazonensis by directing CD40 ligand to macrophages. Infect. Immun. 69:3255-3263.
8. Choi, C. M., and E. A. Lerner. 2002. Leishmaniasis: recognition and management with a focus on the immunocompromised patient. Am. J. Clin. Dermatol. 3:91-105.
9. Conrad, S. M., D. Strauss-Ayali, A. E. Field, M. Mack, and D. M. Mosser. 2007. Leishmania-derived murine MCP-1 enhances the recruitment of a restrictive population of CCR2-positive macrophages. Infect. Immun. 75: 653-665. (First published 6 November 2006; doi:10.1128/IAI.01314-06.)
10. Cosman, D. 1994. A family of ligands for the TNF receptor superfamily. Stem Cells 12:440-455.
11. Dumas, C., A. Muyombwe, G. Roy, C. Matte, M. Olivier, M. Ouellette, and B. Papadopoulou. 2003. Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect. Immun. 71:6499-6509.
12. Ferlin, W. G., D. A. Ferrick, R. L. Coffman, T. der Weid, F. Cottrez, and M. C. Howard. 1998. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb. Eur. J. Immunol. 28:525-531.
13. Grewal, I. S., M. B. Oldstone, R. A. Flavell, P. Borrow, and E. G. Pamer. 1997. The CD40-CD154 system in anti-infective host defense. Curr. Opin. Immunol. 9:491-497.
14. Gurunathan, S., E. Thomas, J. I. Cohen, N. P. Restifo, K. R. Irvine, C. Y. Wu, C. Prussin, and R. A. Seder. 1998. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J. Immunol. 161:4563-4571.
15. Handman, E., R. Ceredig, and G. F. Mitchell. 1979. Murine cutaneous leishmaniasis: disease patterns in intact and nude mice of various genotypes and examination of some differences between normal and infected macrophages. Aust. J. Exp. Biol. Med. Sci. 57:9-29.
16. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley. 1989. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:59-72.
17. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. USA 88:7011-7015.
18. Horton, R. M., L. R. Pease, Z. L. Cai, and S. N. Ho. 1990. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. BioTechniques 8:528-535.
19. Horton, R. M., J. K. Pullen, L. R. Pease, H. D. Hunt, and S. N. Ho. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68.
20. Kamanaka, M., K. Yoshida, T. Kishimoto, T. Kawabe, P. Yu, T. Yasui, T. Horii, and H. Kikutani. 1996. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 4:275-281.
21. Kato, T., R. Hakamada, H. Vantane, and H. Nariuchi. 1996. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J. Immunol. 156:3932-3938.
22. Kelsall, B. L., W. Strober, E. Stuber, and M. Neurath. 1997. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann. N. Y. Acad. Sci. 795:116-126.
23. Kopf, M., F. Brombacher, G. Kohler, G. Kienzle, K. H. Widmann, K. Lefrang, C. Humborg, B. Ledermann, and W. Solbach. 1996. IL-4-deficient Balb/c mice resist infection with Leishmania major. J. Exp. Med. 184:1127-1136.
24. Locksley, R. M., F. P. Heinzel, M. D. Sadick, B. J. Holaday, and K. D. Gardner, Jr. 1987. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann. Inst. Pasteur Immunol. 138:744-749.
25. Lucas, M., X. Zhang, V. Prasanna, and D. M. Mosser. 2005. ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J. Immunol. 175:469-477.
26. Marovich, M. A., T. B. Nutman, M. A. McDowell, and E. K. Thomas. 2000. IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/CD40 ligand-dependent process. J. Immunol. 164: 5858-5865.
27. Mazzei, G. J., P. Graber, B. Allet, S. Lecoanet-Henchoz, J. F. Gauchat, M. D. Edgerton, C. Losberger, A. Durandy, and A. Bernard. 1995. Recombinant soluble trimeric CD40 ligand is biologically active. J. Biol. Chem. 270:7025-7028.
28. Melby, P. C. 2002. Vaccination against cutaneous leishmaniasis: current status. Am. J. Clin. Dermatol. 3:557-570.
29. Miles, S. A., S. M. Conrad, R. G. Alves, S. M. Jeronimo, and D. M. Mosser. 2005. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J. Exp. Med. 201:747-754.
30. Murray, H. W., E. B. Brooks, J. L. DeVecchio, and F. P. Heinzel. 2003. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 47:2513-2517.
31. Murray, H. W., C. M. Lu, E. B. Brooks, R. E. Fichtl, J. L. DeVecchio, and F. P. Heinzel. 2003. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect. Immun. 71:6453-6462.
32. Murray, H. W., B. Y. Rubin, and C. D. Rothermel. 1983. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J. Clin. Investig. 72:1506-1510.
33. Pearson, R. D., S. M. Lareau, and S. M. Jeronimo. 1999. Leishmaniasis at the End of the Millennium. Curr. Infect. Dis. Rep. 1:448-452.
34. Ramesh, N., S. Lederman, L. Chess, M. J. Yellin, R. Fuleihan, V. Ramesh, R. S. Geha, S. Sharma, and F. S. Rosen. 1993. Deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1). Int. Immunol. 5:769-773.
35. Reis e Sousa, H. Charest, D. Jankovic, A. Sher, S. Hieny, T. Scharton-Kersten, and R. N. Germain. 1997. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J. Exp. Med. 186:1819-1829.
36. Sacks, D., J. A. Louis, and D. F. Wirth. 1993. Leishmaniasis, p. 237-268. In K. S. Warren (ed.), Immunology and molecular biology of parasitic infections. Blackwell Science, Inc., Maiden, MA.
37. Sadick, M. D., F. P. Heinzel, B. J. Holaday, R. T. Pu, R. S. Dawkins, and R. M. Locksley. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J. Exp. Med. 171:115-127.
38. Scott, P. 2005. Immunologic memory in cutaneous leishmaniasis. Cell Microbiol. 7:1707-1713.
39. Scott, P., and C. A. Hunter. 2002. Dendritic cells and immunity to leishmaniasis and toxoplasmosis. Curr. Opin. Immunol. 14:466-470.
40. Sher, A., D. L. Sacks, and P. A. Scott. 1983. Host and parasite factors influencing the expression of cutaneous leishmaniasis. Ciba Found. Symp. 99:174-189.
41. Soong, L., P. Kima, N. H. Ruddle, J. Sun, J. C. Xu, I. S. Grewal, R. A. Flavell, B. J. Longley, and D. McMahon-Pratt. 1996. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4:263-273.
42. Tobin, J. F., S. Zheng, R. M. Locksley, C. L. Leptak, S. L. Reiner, F. Hatam, and D. F. Wirth. 1993. Transfected Leishmania expressing biologically active IFN-gamma. J. Immunol. 150:5059-5069.
43. van Kooten, C., and J. Banchereau. 2000. CD40-CD40 ligand. J. Leukoc. Biol. 67:2-17.